InVitro International Q3 Sales Plunge 24%, Net Income Drops 82%
IVRO has more than doubled off its 52-week low of $0.025.
Summary
InVitro International reported Q3 FY26 sales of $117,760, down 24.1% year-over-year, with net income collapsing 81.7% to just $8,476. The company noted this was the weakest three-month stretch in recent years, reversing prior trends. CEO Ulmer pointed to regulatory tailwinds for non-animal testing but offered no concrete recovery plan. With a market cap of only $1.5M and shares at $0.0679, the sharp deterioration raises immediate viability concerns.
At the time of this announcement, IVRO was trading at $0.07 on OTC in the Life Sciences sector, with a market capitalization of approximately $1.5M. The 52-week trading range was $0.03 to $0.16. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: TMX Newsfile.